Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next-Gen Smallpox, Anthrax Vaccines To Be First Use Of Animal Efficacy

Executive Summary

A next-generation smallpox vaccine is expected to be the first product licensed under FDA's animal efficacy rule, HHS Office of the Assistant Secretary for Public Health Emergency Preparedness Senior Advisor Philip Russell, MD, said Aug. 28

You may also be interested in...



Wyeth Dryvax Smallpox Vaccine Approved For 100-Dose Kit, 30-Day Expiration

Wyeth's Dryvax may be used for up to 30 days after reconstitution following a supplemental approval for the smallpox vaccine

Wyeth Dryvax Smallpox Vaccine Approved For 100-Dose Kit, 30-Day Expiration

Wyeth's Dryvax may be used for up to 30 days after reconstitution following a supplemental approval for the smallpox vaccine

Anthrax Vaccine Plan: VaxGen, Avecia To Produce 4,000 Test Doses In March

VaxGen and Avecia each expect to produce 2,000 test doses of recombinant anthrax vaccine by the end of March under separate contracts with NIH's National Institute of Allergy & Infectious Diseases

Related Content

UsernamePublicRestriction

Register

PS040416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel